| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.09 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.09 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.086 | 0.1 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |